Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

pembrolizumab 241 Carboplatin 167 Injections 138 Paclitaxel 119 Gemcitabine 116 Bevacizumab 112 Cisplatin 105 Docetaxel 82 Cyclophosphamide 78 Pemetrexed 76 Capecitabine 69 Fluorouracil 67 Oxaliplatin 65 Fulvestrant 57 fludarabine 55 Nivolumab 55 Leucovorin 52 Cetuximab 52 130-nm albumin-bound paclitaxel 47 Dexamethasone 46 Rituximab 41 atezolizumab 37 venetoclax 35 Drug Therapy 35 toripalimab 34 enzalutamide 34 Irinotecan 34 durvalumab 32 Prednisone 32 Letrozole 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × INDUSTRY × remibrutinib × Clear all

NCT06744920 2026-06-01

RELIEVE

Novartis

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡